EP
FATE icon

EPIQ Partners’s Fate Therapeutics FATE Stock Holding History

EPIQ Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,366
Closed -$36.3K – 77
2024
Q3 		$36.3K Buy
+10,366
New +$40.3K 0.02% 77
2024
Q2 		– Sell
-10,071
Closed -$73.9K – 74
2024
Q1 		$73.9K Hold
10,071
– – 0.05% 74
2023
Q4 		$37.7K Buy
+10,071
New +$23.8K 0.03% 68
2023
Q3 		– Sell
-10,071
Closed -$47.9K – 70
2023
Q2 		$47.9K Buy
+10,071
New +$55.6K 0.03% 76
2023
Q1 		– Sell
-71,521
Closed -$722K – 78
2022
Q4 		$722K Sell
71,521
-1,245
-2% -$23.4K 0.48% 46
2022
Q3 		$1.63M Buy
72,766
+3,973
+6% +$115K 1.01% 37
2022
Q2 		$1.71M Buy
68,793
+10,985
+19% +$303K 1.04% 36
2022
Q1 		$2.24M Buy
57,808
+9,205
+19% +$356K 1.21% 34
2021
Q4 		$2.84M Sell
48,603
-235
-0.5% -$13.3K 1.52% 23
2021
Q3 		$2.9M Sell
48,838
-847
-2% -$66.4K 1.33% 27
2021
Q2 		$4.31M Buy
49,685
+2,930
+6% +$236K 2.16% 13
2021
Q1 		$3.85M Buy
46,755
+3,287
+8% +$315K 2.21% 14
2020
Q4 		$3.95M Buy
43,468
+5,205
+14% +$323K 2.75% 10
2020
Q3 		$1.7M Buy
+38,263
New +$1.34M 1.28% 32

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EPIQ Partners's FATE Position: Q4 2024 in Review

EPIQ Partners sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 10,366 shares — an estimated $36.3K sold.

EPIQ Partners first reported a position in FATE in Q3 2020 and held it in 14 quarters. The position peaked at $4.31M in Q2 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • EPIQ Partners reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EPIQ Partners sold 10,366 Fate Therapeutics shares in Q4 2024, an estimated $36.3K.
  • EPIQ Partners first reported a position in Fate Therapeutics in Q3 2020 and held it in 14 quarters.
  • EPIQ Partners's Fate Therapeutics position peaked at $4.31M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on EPIQ Partners's 13F filing for Q4 2024, filed 22 Jan 2025.